USO 25003
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localized High-Risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy (EvoPAR-Prostate02) (D9727C00001)
Disease Types: Genitourinary Cancer Research
Eligibility Requirements:
• Histologically confirmed prostate cancer
• Subjects must have newly diagnosed high-risk or very high-risk
disease or a high-risk BCR following radical prostatectomy
• Subjects must have confirmed BRCA1 or BRCA2 mutation status
• Subjects are required to have a CT or MRI, a bone scan, and a
PSMA-PET following the completion of their planned RT to confirm
NED or evidence of disease confined to the pelvis (M0)
• Subjects with a history of MDS/AML or with features suggestive of
MDS/AML are excluded
• Subjects that have received any prior chemotherapy,
immunotherapy, or treatment with a PARP inhibitor are excluded
For more information on this trial CLICK HERE .
Available at: